Sanofi (SNY)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 50.84 |
| Open | 50.90 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1800 |
| Day's range | 50.44 - 51.76 |
| 52-week range | 45.17 - 54.26 |
| Volume | |
| Avg. volume | 1,563,298 |
| Market cap | 128.762B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 18.52 |
| EPS (TTM) | 2.78 |
| Earnings date | N/A |
| Forward dividend & yield | 1.93 (3.75%) |
| Ex-dividend date | 03 May 2021 |
| 1y target est | 63.63 |
- Zacks
Regeneron (REGN) Rides on Solid Product Portfolio: Should You Buy?
Regeneron (REGN) is expected to maintain momentum on the back of a solid and diverse portfolio. The promising pipeline also sets the stage for further growth.
- Zacks
Pharma Stock Roundup: GSK's Consumer Unit Offer Rejection, FDA Updates for AZN, PFE
Glaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.
- Zacks
Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal (Revised)
Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.
© 2022 Yahoo. All rights reserved.
